RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody takes aim at tough lymphoma
Disease control OngoingThis early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy aims to tackle returning lymphoma
Disease control OngoingThis phase II trial is testing whether combining rituximab and pembrolizumab, with or without lenalidomide, can help patients with follicular lymphoma or diffuse large B-cell lymphoma that has returned after previous treatment. The study enrolls 53 participants and measures how m…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to tackle tough lymphoma
Disease control TerminatedThis phase 2 trial tests the safety and effectiveness of combining two drugs, epcoritamab and tazemetostat, for patients with follicular lymphoma that has relapsed or is refractory. The study plans to enroll 33 adults. Epcoritamab helps the immune system attack cancer cells, whil…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo tackles tough lymphomas
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…
Matched conditions: RECURRENT GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC